Q2 2021 results in line with preliminary announcement Net sales up 28 24 CER to 567.3 million adjusted diluted EPS up 22 to 0.67 0.66 CERVery strong non-COVID product group sales 52 CER growth in Q2 2021 to 407.6 million representing 72 of total sales expect at least 20 CER full-year growthExcellent cash flow results H1 2021 operating cash flow rises 89 to 285.0 million and free cash flow up 94 to 195.0 millionFull-year 2021 outlook for at least 12 CER sales growth and at least 2.42 CER adjusted diluted EPS as announced on July 12New 100 million share repurchase program startedQIAGEN N.V. announced full results for the second quarter and first half of 2021 that were in line with the preliminary announcement on July 12.Net sales rose 28 24 at constant exchange rates CER to 567.3 million in Q2 2021 and above the outlook for about 20 CER growth. Currency movements against the U.S. dollar had a positive impact of about four percentage points on sales at actual rates in Q2 2021 over the year-ago period. For the first half of 2021 net sales rose 39 35 CER to 1.135 billion. Diluted earnings per share EPS were 0.52 in the second quarter of 2021 while adjusted EPS were 0.67 0.66 CER against the outlook for about 0.62-0.64 CER and were up 22 from 0.55 in the second quarter of 2020. For the first half of 2021 diluted EPS were 1.08 while adjusted EPS were 1.33 1.31 CER up 49 from 0.89 in the first half of 2020.In line with the preliminary announcement in mid-July our results in the second quarter of 2021 were driven by outstanding performance in our non-COVID product groups and show solid trends for our core business. We are seeing very positive growth in these product groups which are the highest priority of our teams as we seek to expand on the opportunities within QIAGENs five pillars of growth. We anticipate ongoing strong demand in these product groups in the second half of 2021 as we aim for at least 20 CER growth for the full year and for these product groups to represent the majority of our sales said Thierry Bernard Chief Executive Officer of QIAGEN N.V.We welcome the success of vaccination campaigns and their contributions to moving the world beyond the pandemic. At the same time the faster-than-expected uptake has led to a reduction in demand for COVID-19 testing. This prompted us earlier in July to update our view on COVID-19 testing trends for the second half of 2021 and update the outlook for sales and adjusted EPS growth. As we prepare QIAGEN for sustained growth beyond the pandemic and reaffirm the mid-term targets set for our five pillars of growth we are confident in developing a stronger and more differentiated leadership position in the Life Sciences and diagnostics markets Bernard said.Roland Sackers Chief Financial Officer of QIAGEN N.V. said QIAGEN continued to deliver a strong level of sales growth and profitability throughout the first half of 2021 and also very strong cash flow improvements over the year-ago period. As part of our commitment to value creation we recently started the new 100 million share repurchase program with a goal for completion in mid-September 2021. This reflects our confidence in QIAGENs growth prospects and is a reaffirmation of our commitment to increasing returns for shareholders.
🔍 Key Information
📄
Tender Reference No.
464451313
📅
Publication Date
06 Aug 2021
🌐
Sector
Banking, Finance, Insurance and Securities (BFIS)
📝
Notice Type
News
📍
Location
Netherlands
📁
Documents & Downloads
No documents found
🏷️ CPV
No CPV found
Need help with this bid?
Our bid experts can help you find, evaluate & win more tenders.